In vivo radiosensitizing effect of the adenovirus E1A gene in murine and human malignant tumors

Int J Oncol. 1999 Dec;15(6):1163-8. doi: 10.3892/ijo.15.6.1163.


The adenovirus E1A gene is a potent inducer of chemosensitivity and radiosensitivity through p53-dependent and independent mechanisms. We have studied the sensitivity of murine (MSC11A5, a sarcomatoid epidermoid carcinoma) and human (HeLa, human cervix carcinoma) E1A-expressing tumors, in vivo, after treatment with cisplatin or gamma-irradiation. In athymic mice, half-body irradiation was performed in an AECL Cobalt unit, at an SSD of 80 cm. Daily fractions of 300 cGy over 3 days, up to a total dose of 9 Gy. Cisplatin was injected intraperitoneally at a dose of 9 mg per kg of body weight. After gamma-irradiation or intraperitoneal injection of cisplatin, about 30% of the E1A-expressing tumors regressed completely or were associated with a marked decrease in tumorigenicity over the following weeks. We conclude that malignant tumors, when expressing adenovirus E1A, are very sensitive to treatment with DNA-damaging agents, in vivo, regardless of the p53 status of the tumors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenovirus E1A Proteins / genetics*
  • Animals
  • Antineoplastic Agents / therapeutic use
  • Cisplatin / therapeutic use
  • Combined Modality Therapy
  • Female
  • Gamma Rays
  • Gene Expression Regulation, Neoplastic / radiation effects
  • HeLa Cells
  • Humans
  • Injections, Intraperitoneal
  • Mice
  • Mice, Nude
  • Mutation
  • Neoplasm Transplantation
  • Neoplasms, Experimental / genetics
  • Neoplasms, Experimental / pathology
  • Neoplasms, Experimental / radiotherapy*
  • Transplantation, Heterologous
  • Tumor Cells, Cultured
  • Tumor Suppressor Protein p53 / genetics


  • Adenovirus E1A Proteins
  • Antineoplastic Agents
  • Tumor Suppressor Protein p53
  • Cisplatin